scholarly journals Feasibility and Safety of Percutaneous Cardiac Interventions for Congenital and Acquired Heart Defects in Infants ≤1000 g

Children ◽  
2021 ◽  
Vol 8 (9) ◽  
pp. 826
Author(s):  
Ranjit Philip ◽  
Jeffrey Towbin ◽  
Neil Tailor ◽  
Vijaya Joshi ◽  
Jason N. Johnson ◽  
...  
Keyword(s):  
Adverse Event ◽  
Patent Ductus Arteriosus ◽  
Congenital Heart Defects ◽  
Congenital Heart ◽  
Transcatheter Closure ◽  
Heart Defects ◽  
Ductus Arteriosus ◽  
Major Adverse Event ◽  
Procedural Success ◽  
Patent Ductus

The transcatheter closure of patent ductus arteriosus (TCPC) has been demonstrated to be feasible even in infants weighing ≤1000 g. However, other percutaneous cardiac interventions (PCI) for such small infants born with congenital heart defects (CHD) or acquired heart defects (AHD) have not been well described. The purpose of this study was to describe the feasibility and safety of PCI in infants ≤1000 g. A retrospective review was conducted between June 2015 and May 2021, looking at 148 consecutive PCIs performed on infants weighing ≤1000 g at the time of the procedure. The procedural success rate was 100%. The major adverse event (AE) rate for TCPC was 3%, while there were no major AEs for other PCI. It is feasible to perform PCIs in infants weighing ≤1000 g with CHD and AHD using currently available technologies.

scholarly journals Intravenous Indomethacin Therapy in Infants With a Patent Ductus Arteriosus Complicating Other Congenital Heart Defects

2003 ◽  
Vol 67 (9) ◽  
pp. 750-752 ◽  
Author(s):  
Ken Watanabe ◽  
Hideshi Tomita ◽  
Yasuo Ono ◽  
Osamu Yamada ◽  
Ken-ichi Kurosaki ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Congenital Heart Defects ◽  
Congenital Heart ◽  
Heart Defects ◽  
Ductus Arteriosus ◽  
Patent Ductus

scholarly journals Safety and Procedural Success of Transcatheter Closure of Patent Ductus Arteriosus in Adults at Shahid Gangalal National Heart Centre, Kathmandu, Nepal

2020 ◽  
Vol 17 (2) ◽  
pp. 43-46
Author(s):  
Chandra Mani Adhikari ◽  
Amrit Bogati ◽  
Kiran Prasad Acharya ◽  
Manish Shrestha ◽  
Urmila Shakya ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Transcatheter Closure ◽  
Ductus Arteriosus ◽  
Adult Patients ◽  
Device Closure ◽  
Cardiac Catheterization Laboratory ◽  
National Heart ◽  
Procedural Success ◽  
Device Size ◽  
Patent Ductus

Background and Aims: Transcatheter closure of patent ductus arteriosus (PDA) using either coils or device is a well-established procedure. PDA is one of the common congenital heart diseases and it is not uncommon for it to be diagnosed in adulthood. However, only few studies are conducted in our part of the world regarding the safety and procedural success of device closure of PDA in adults. We aim to assess safety and procedural success of transcatheter closure of PDA in adults at Shahid Gangalal National Heart Centre, Kathmandu, Nepal. Methods: It was a single center, retrospective study. Cardiac catheterization laboratory records of all consecutive adult patients (age ≥ 18 years) who underwent PDA device closure between March 2007 to March 2020 were reviewed. Patients age, gender, device size and device type along with procedural success of the procedure were reviewed. Any complication recorded was reviewed. Results: During the study period 118 adult patients were attempted for transcatheter closure of PDA. In three cases transcatheter closure was not attempted. In one patients attempt was made to close the duct with cook coil which embolized to pulmonary artery. PDA was successfully closed in 114 patients. Among the 114 patients, 87 were females and 27 were male. Age ranged from 18 to 69 years with mean age was 29.5 years. PDA size ranged from 3mm to 18mm with the mean of 6.9mm. In two patients, residual PDA after surgical closure were closed. Amplatzer duct occluder was the most commonly used device used in 89 (78%) patients followed by Memopart PDA device in 11 (9.6%) patients, Amplatzer Muscular VSD occluder in four patients. Device size of “8x10” in 32 patients and “10x12” device in 29 patients, were the most commonly used device size. Conclusion: Transcatheter closure of PDA in adults can safely be done with high success rate.

scholarly journals Transcatheter closure of patent ductus arteriosus using duct occluder: an eleven-year experience from a single tertiary cardiac center

2019 ◽  
Vol 7 (8) ◽  
pp. 2894
Author(s):  
Achyut Sarkar ◽  
Neha Rani ◽  
Prashant Kumar ◽  
Shyam Sundar Chaudhary ◽  
Suman Chatterjee
Keyword(s):  
Patent Ductus Arteriosus ◽  
Transcatheter Closure ◽  
Postgraduate Medical Education ◽  
Ductus Arteriosus ◽  
Volume Overload ◽  
Residual Shunt ◽  
Term Outcome ◽  
Procedural Success ◽  
Patent Ductus

Background: Patent Ductus Arteriosus (PDA) is a common congenital disorder. As an isolated lesion, PDA constitutes 6 to 11% of all congenital heart disease. PDA needs closure to eliminate pulmonary over circulation leading to volume overload of left ventricle, pulmonary vascular obstructed disease.Methods: This retrospective study was carried out in pediatric cardiology unit of Institute of Postgraduate Medical Education and Research, Kolkata from September 2005 to August 2016, which included 503 patients.Results: Device closure was attempted in 492 patient’s Procedural success was achieved in 85% cases on table, in who check aortogram revealed complete closure of PDA. In 15% cases, residual shunt was present. In 12% of cases, residual shunt disappeared during follow-up echocardiogram over 6-month follow-up. In 3% cases, small shunt remained at 6-month and 1-year follow up.Conclusion: Transcatheter closure of PDA by duct occluder is safe and effective with good mid-term outcome. The optimum assessment of ductul size and anatomy is crucial for optimum device size, which prevents residual shunt, device embolization and protrusion.

scholarly journals Patent Ductus Arteriosus: An Overview

2007 ◽  
Vol 12 (3) ◽  
pp. 138-146 ◽  
Author(s):  
James E. Dice ◽  
Jatinder Bhatia
Keyword(s):  
Patent Ductus Arteriosus ◽  
Preterm Infants ◽  
Congenital Heart ◽  
Heart Defects ◽  
Ductus Arteriosus ◽  
Clinical Signs ◽  
Medical Intervention ◽  
Fluid Restriction ◽  
Term Infants ◽  
Patent Ductus

Patent ductus arteriosus (PDA) is one of the most common congenital heart defects, accounting for 5%–10% of all congenital heart disease in term infants. The occurrence of PDA is inversely related to gestational age and weight, with an even greater incidence in preterm infants. The maintenance of ductal patency is essential for the normal development of the fetus. In the neonate, however, persistent patency of the ductus arteriosus (DA) is associated with significant morbidity and mortality. Normally, at birth, the DA constricts, resulting in intraluminal ischemic hypoxia, which eventually leads to closure and remodeling of the ductus. PDA in term infants is usually associated with a functional defect, whereas in preterm infants it is associated with immaturity. Normal physiologic mechanisms contributing to closure - oxygen tension and decreased prostaglandins—are altered in prematurity. Clinical signs of ductal patency include murmur, tachycardia, bounding peripheral pulses, and congestive heart failure and associated symptoms. Symptoms are not always present; therefore, diagnostic imaging is critical if a PDA is suspected on clinical grounds. Three management strategies are currently available for PDA: fluid restriction and diuretics (as clinically appropriate), medical intervention, and surgical ligation. Pharmacologic closure can be achieved via administration of intravenous indomethacin or ibuprofen lysine. While both agents have shown similar efficacy, ibuprofen lysine has demonstrated an improved safety profile, particularly in terms of renal effects, compared to indomethacin.

scholarly journals Congenital heart defects in dogs: A retrospective study of 301 dogs

2017 ◽  
Vol 73 (10) ◽  
pp. 651-656
Author(s):  
Magdalena Garncarz ◽  
Marta Parzeniecka-Jaworska ◽  
Olga Szaluś-Jordanow
Keyword(s):  
Retrospective Study ◽  
Congenital Heart Defects ◽  
Medical Records ◽  
Congenital Heart ◽  
Septal Defect ◽  
Early Recognition ◽  
Heart Defects ◽  
Ductus Arteriosus ◽  
Subaortic Stenosis ◽  
Patent Ductus

The aim of the study was to assess the frequency of congenital heart defects in a population of dogs in Poland and to determine which breeds were affected by particular defects. A retrospective study of the medical records of cardiologically examined dogs revealed 301 cases of echocardiographically confirmed congenital heart defects. Dogs with congenital heart defects made up 2.7% of the dogs that underwent a cardiologic examination. The age at diagnosis ranged from 2 weeks to 190 months. Mixed breeds (33 dogs, 11%), Bull Terriers (31, 10%), Boxers (28, 9%), German Shepherds (17, 6%), Yorkshire Terriers (17, 6%), and French Bulldogs (16, 5%) were the most frequently affected breeds. Subaortic stenosis (120 cases, 33.9%), pulmonic stenosis (64, 18.1%), patent ductus arteriosus (59, 16.7%), mitral valve dysplasia (56, 15.8%), ventricular septal defect (24, 6.8%) and tricuspid valve dysplasia (17, 4.8%) were the most frequent congenital heart defects recognized in this study. Isolated congenital heart disease occurred in 258 dogs (86%), while multiple heart defects were noted in 43 dogs (14%). Most (60%) congenital heart defects were recognized in dogs older than 1 year. Early recognition of congenital heart defects is important for better patient care. Collecting information on the frequency of congenital heart defects in particular breeds will be useful in educating breeders and thus in improving the overall health of the breed.

scholarly journals Transcatheter closure of tubular type patent ductus arteriosus using Amplatzer® ductal occluder II: a case report

2016 ◽  
Vol 53 (5) ◽  
pp. 291
Author(s):  
Mulyadi M Djer ◽  
Nikmah Salamia Idris ◽  
Angelina Angelina
Keyword(s):  
Patent Ductus Arteriosus ◽  
Congenital Heart ◽  
Transcatheter Closure ◽  
Heart Diseases ◽  
Ductus Arteriosus ◽  
Preterm Neonates ◽  
Congenital Heart Diseases ◽  
Residual Shunt ◽  
Tubular Type ◽  
Patent Ductus

Patent ductus arteriosus (PDA) is a common congenital heart disease, accounting for 5-10% of all congenital heart diseases. The incidence of PDA is even higher in preterm neonates, ranging from 20-60%.1-4 Closure of PDA is indicated in all cases, except for duct-dependent congenital heart diseases or PDA with Eisenmenger syndrome.1,5,6 In small asymptomatic PDAs, closure is indicated to prevent the risk of complications, such as endarteritis, endocarditis, aneurysm of ductus arteriosus, or congestive heart failure.1,2,7In recent years, interventional cardiology has become a gold standard therapy for the majority of PDA cases beyond neonatal age. Since its introduction in 1967, many devices and methods have been developed to allow transcatheter closure of virtually all PDAs, regardless of size or configuration. Nevertheless, the tubular shape (type C) PDA, which has the highest residual shunt rate, still poses a great challenge for the interventionist.8-10 The second generation of Amplatzer® device occluders (ADO II), released in 2007, has been suggested to be effective in closing tubular PDAs.10 The purpose of this study was to report the initial clinical experience using ADO II to close a tubular type PDA in Indonesia.

scholarly journals Transcatheter closure of Patent ductus arteriosus in a child with IVC interruption through standard femoral access: a case report

2020 ◽  
Vol 72 (1) ◽  
Author(s):  
Sanjeev H. Naganur ◽  
C. R. Pruthvi ◽  
Dinakar Bootla ◽  
Krishna Prasad ◽  
V. Krishna Santosh ◽  
...  
Keyword(s):  
Case Report ◽  
Patent Ductus Arteriosus ◽  
Transcatheter Closure ◽  
Ductus Arteriosus ◽  
Femoral Access ◽  
Patent Ductus

scholarly journals A Framework for AI-Assisted Detection of Patent Ductus Arteriosus from Neonatal Phonocardiogram

Healthcare ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 169
Author(s):  
Sergi Gómez-Quintana ◽  
Christoph E. Schwarz ◽  
Ihor Shelevytsky ◽  
Victoriya Shelevytska ◽  
Oksana Semenova ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Heart Defects ◽  
Ductus Arteriosus ◽  
Area Under The Curve ◽  
Clinical Decision ◽  
Heart Sounds ◽  
Decision Tree Classifier ◽  
Support Tool ◽  
Tree Classifier ◽  
Patent Ductus

The current diagnosis of Congenital Heart Disease (CHD) in neonates relies on echocardiography. Its limited availability requires alternative screening procedures to prioritise newborns awaiting ultrasound. The routine screening for CHD is performed using a multidimensional clinical examination including (but not limited to) auscultation and pulse oximetry. While auscultation might be subjective with some heart abnormalities not always audible it increases the ability to detect heart defects. This work aims at developing an objective clinical decision support tool based on machine learning (ML) to facilitate differentiation of sounds with signatures of Patent Ductus Arteriosus (PDA)/CHDs, in clinical settings. The heart sounds are pre-processed and segmented, followed by feature extraction. The features are fed into a boosted decision tree classifier to estimate the probability of PDA or CHDs. Several mechanisms to combine information from different auscultation points, as well as consecutive sound cycles, are presented. The system is evaluated on a large clinical dataset of heart sounds from 265 term and late-preterm newborns recorded within the first six days of life. The developed system reaches an area under the curve (AUC) of 78% at detecting CHD and 77% at detecting PDA. The obtained results for PDA detection compare favourably with the level of accuracy achieved by an experienced neonatologist when assessed on the same cohort.

Sign in / Sign up

Export Citation Format

Share Document